Cyclophosphamide, fludarabine (DrugBank: Cyclophosphamide, Fludarabine)
18 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
19 | Lysosomal storage disease | 0 |
28 | Systemic amyloidosis | 0 |
36 | Epidermolysis bullosa | 0 |
46 | Malignant rheumatoid arthritis | 0 |
49 | Systemic lupus erythematosus | 0 |
51 | Scleroderma | 0 |
60 | Aplastic anemia | 2 |
61 | Autoimmune hemolytic anemia | 0 |
62 | Paroxysmal nocturnal hemoglobinuria | 0 |
65 | Primary immunodeficiency | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
96 | Crohn disease | 0 |
164 | Oculocutaneous albinism | 0 |
283 | Acquired pure red cell aplasia | 0 |
284 | Diamond-Blackfan anemia | 0 |
285 | Fanconi anemia | 2 |
326 | Osteopetrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01129323 (ClinicalTrials.gov) | November 2009 | 21/4/2010 | Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia | Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: Cyclophosphamide, Fludarabine, Rabbit ATG | City of Hope Medical Center | NULL | Withdrawn | N/A | 21 Years | Both | 0 | N/A | United States |
2 | NCT00882323 (ClinicalTrials.gov) | November 2008 | 15/4/2009 | Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA) | Reduced Toxicity Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia | Aplastic Anemia | Drug: Cyclophosphamide, Fludarabine, Thymoglobulin | The Korean Society of Pediatric Hematology Oncology | NULL | Recruiting | 1 Year | 21 Years | Both | 33 | Phase 2 | Korea, Republic of |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00167206 (ClinicalTrials.gov) | March 2004 | 9/9/2005 | Stem Cell Transplantation for Fanconi Anemia | A Study of Thymic Shielding in Recipients of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Stem Cell Transplantation in Patients With Fanconi Anemia | Fanconi Anemia | Procedure: Hematopoietic Stem Cell Transplant;Procedure: Thymic Shielding During Radiation;Procedure: Total Body Irradiation;Drug: Cyclophosphamide, Fludarabine | Masonic Cancer Center, University of Minnesota | NULL | Terminated | N/A | 18 Years | All | 16 | Phase 1;Phase 2 | United States |
2 | NCT00630253 (ClinicalTrials.gov) | February 17, 2000 | 5/3/2008 | Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia | A Study of Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed by Matched Sibling Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia | Fanconi Anemia | Biological: Anti-Thymocyte Globulin;Drug: Cyclophosphamide;Drug: Fludarabine;Procedure: Hematopoietic Stem Cell Transplantation;Drug: Methylprednisolone;Drug: Filgrastim;Drug: Cyclosporine;Drug: Mycophenolate Mofetil | Masonic Cancer Center, University of Minnesota | NULL | Completed | N/A | 59 Years | All | 31 | Phase 1;Phase 2 | United States |